BackInozyme Pharma Overview

Inozyme Pharma Inventory

Track Inozyme Pharma's inventory ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Inventory
$0.00

Peer average

Loading

Inozyme Pharma Inventory History

Loading

Inozyme Pharma vs. peers: Inventory Comparison

Loading

Inozyme Pharma Inventory Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Inozyme Pharma (INZY) FAQ

Inozyme Pharma's inventory stands at $0 as of March 2025. In the prior-year period, the figure was $0. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Inozyme Pharma reported $0 in inventory versus $0 a year earlier. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

In the prior-year period, the figure was $0. Sustained growth in inventory can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Inozyme Pharma's inventory evolved across reporting periods, while the comparison chart places INZY next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, inventory is commonly used to spot outliers. Inozyme Pharma's reading of $0 is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.